Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listElamipretide

Elamipretide

  • CAS NO.:736992-21-5
  • Empirical Formula: C32H49N9O5
  • Molecular Weight: 639.79
  • MDL number: MFCD20133791
  • EINECS: 205-858-1
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-19 20:33:22
Elamipretide Structural

What is Elamipretide?

Description

Elamipretide, also known as MTP 131, is a mitochondria-targeted peptide antioxidant. Elamipretide decreases inflammation and protect against a variety of neurological illnesses. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. Elamipretide Promotes Mitophagosome Formation and Prevents Its Reduction Induced by Nutrient Excess in INS1 β-cells.

The Uses of Elamipretide

D-Arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide-d5 Trifluoroacetic Acid Salt is labelled D-Arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide (A769700) which is a mitochondrial-targeted compound that re-energizes ischemic mitochondria by interacting with cardiolipin. It is a cell-permeable antioxidant peptide.

Mechanism of action

Elamipretide can inhibit the production of pathogenic ROS (reactive oxygen species) and restore mitochondrial ATP synthesis. Currently, the most accepted mechanism for these two actions is the direct interaction between Elamipretide and cardiolipin.

Clinical Use

Barth syndrome is an ultra-rare genetic condition characterized by cardiac abnormalities leading to exercise intolerance, muscle weakness, debilitating fatigue, heart failure, recurrent infections, and delayed growth. There are currently no FDA- or EMA-approved therapies for patients with Barth syndrome. Elamipretide has an Orphan Drug, Fast Track and Rare Pediatric Designation from the FDA and Orphan Drug Designation from the EMA for treating Barth syndrome.

Side Effects

Side effects of elamipretide include:
Mild redness or itching at the injection site
Headache
Dizziness

Properties of Elamipretide

Density  1.34±0.1 g/cm3(Predicted)
solubility  Methanol (Slightly), Water (Slightly)
pka 10.10±0.25(Predicted)
form  Solid
color  White to Off-White
Stability: Hygroscopic

Safety information for Elamipretide

Computed Descriptors for Elamipretide

InChIKey SFVLTCAESLKEHH-WKAQUBQDSA-N
SMILES C(N)(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=C(C)C=C(O)C=C1C)NC(=O)[C@@H](CCCNC(N)=N)N

Related products of tetrahydrofuran

You may like

  • 1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%
    1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%
    99903-60-3
    View Details
  • 88491-46-7 98%
    88491-46-7 98%
    88491-46-7
    View Details
  • 1823368-42-8 98%
    1823368-42-8 98%
    1823368-42-8
    View Details
  • 2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    1307449-08-6
    View Details
  • Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    25408-95-1
    View Details
  • 2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    1805639-70-6
    View Details
  • 1784294-80-9 98%
    1784294-80-9 98%
    1784294-80-9
    View Details
  • Lithium Clavulanate
    Lithium Clavulanate
    61177-44-4
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.